

# Deal Teaser



## Submitted by

Stefan Drawetz  
Grazer Treuhand Steuerberatung GmbH & Partner KG  
Graz  
s.drawetz@grazertreuhand.at  
+43 316 4780

## Firm

Grazer Treuhand Steuerberatung GmbH & Partner KG

## Email

s.drawetz@grazertreuhand.at

## Jurisdiction

Austria

## Title

Deal Teaser - EVOMEDIS medical company - Austria

## Deadline

20/07/2023

## Distressed Companies

No

## Sector

Austrian biotech company developing new innovative therapies for the treatment of severe burns and chronic wounds

## Active Regions

Austria

**Do you have a direct mandate from the buyer or seller?**

Yes

### # of Employees

Unknown

### Deal Structure

Investment

### Reason For Selling

INDUSTRY WITH CONSOLIDATION OPPORTUNITIES HIGH GROWTH POTENTIAL  
§ Global market is valued at [\$] 9.5 Bn as of 2020 to double until 2030  
§ More than 2.5 million burn victims could benefit from cell based wound therapy  
§ High incidence locations with these type of wounds are Asia, Africa and Latin America  
§ 1 to 2% of the population will experience a chronic wound during their lifetime in developed countries

### Revenue Target

Target investment amount: Equity: €5 MM

### Business Description & Market Information

Great opportunity to deliver cell-based therapy, cost efficient, easily & globally available that leads to reducing hospitalization times

#### 1. About the company:

Incorporated in 2020, EVOMEDIS (short for "Evolutions Medicine") is an Austrian biotech company developing new innovative therapies for the treatment of severe burns and chronic wounds § Has a mixed business model that combines in-house development projects with services provided to partners

EVOCellic: Cell-based regenerative therapy for healing burns and chronic wounds

EVOSens: Patch that functions as a pH sensor for wounds that can drive the decision for adjusting treatments and reduce dressing changes

EVOSource: R&D service platform for wound healing projects in order to support partners and position them in the market based on new knowledge

#### 2. Core Strengths

Network: Strong relationships with excellent research organizations and health care professionals

Knowledge: Deep know-how on wound treatments, regulatory framework and the market

Competence: Highly skilled in drug and medical device development, clinical studies and securing new IP rights

Management: Team formed by professionals specialized in biotech, regenerative medicine and chronic wounds.

## Additional Information

Expected Performance:

§ Positive cash flow in 2030

§ 20%+ Market share in selected countries

§ Important increase in progress expected due to new investments

---

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY. ALTHOUGH SUBMITTER BELIEVES THE INFORMATION HEREIN TO BE CORRECT, NEITHER IT, IR GLOBAL, NOR ANY OTHER IR GLOBAL MEMBER HAS INDEPENDENTLY VERIFIED SUCH INFORMATION OR MAKES ANY REPRESENTATION OR WARRANTY CONCERNING THE ACCURACY OF THE INFORMATION SET FORTH HEREIN.



The Piggery  
Woodhouse Farm  
B92 0DJ  
United Kingdom

+44 1675 443396  
Info@irglobal.com